Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (Nasdaq: CYRX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.
An earnings release and a document titled "Cryoport Third Quarter 2025 in Review" will be issued at 4:05 p.m. ET, followed by a management questions-and-answers conference call at 5:00 p.m. ET the same day. The review document and slide deck will be available in the Investor Relations section at https://ir.cryoportinc.com/news-events/ir-calendar.
The live call dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (International) with conference ID 1120106. A replay will be available online ~three hours after the call and by dial-in until November 11, 2025 (replay numbers: 1-844-512-2921 U.S.; 1-412-317-6671 International).
MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.
The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.
Cryoport (NASDAQ: CYRX) has announced the opening of a new 55,000-square-foot Global Supply Chain Center (GSCC) in Louvres, France, near Paris Charles de Gaulle Airport. The facility represents the company's third global supply chain center campus, strengthening its temperature-controlled supply chain solutions network.
The Paris GSCC will provide 24-hour worldwide dispatch capabilities and immediate logistics support for biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. Future phases will incorporate BioServices, biostorage, QP drug management, and Importer of Record services. The facility's development was partially funded by a grant from the Île-de-France region, with an official grand opening scheduled for November 20, 2025.
Cryoport (NASDAQ: CYRX) reported strong Q2 2025 financial results with total revenue increasing 14% year-over-year to $45.5 million. The company's Commercial Cell & Gene Therapy revenue grew 33% to $8.7 million, while Life Sciences Services revenue rose 21%, including a 28% increase in BioStorage/BioServices revenue.
Key highlights include the completion of a strategic partnership with DHL Group and the divestiture of CRYOPDP, resulting in a significant capital infusion. The company supports 728 global clinical trials, including 82 in Phase 3. Cryoport maintained its full-year 2025 revenue guidance of $165-172 million and reported $426 million in cash and equivalents as of June 30, 2025.
Cryoport (NASDAQ:CYRX), a global leader in temperature-controlled supply chain solutions for the life sciences, has scheduled its Q2 2025 earnings release for August 5, 2025 after U.S. markets close.
The company will release a document titled "Cryoport Second Quarter 2025 in Review" at 4:05 p.m. ET, followed by a Q&A conference call at 5:00 p.m. ET. Management will address questions from the investment community regarding the reported results, accompanied by a slide deck presentation.
The earnings call can be accessed via phone (U.S.: 1-800-717-1738, International: 1-646-307-1865) or webcast through the company's investor relations website. A replay will be available until August 12, 2025.
Cryoport (NASDAQ:CYRX) has announced the launch of its next-generation vapor shippers, the SC 4/2V and SC 4/3V, through its MVE Biological Solutions division. The new models feature significant improvements in hold times, with the SC 4/2V extending from 13 to 19 days and the SC 4/3V from 21 to 26 days.
The enhanced vapor shippers incorporate several innovative features, including the patented BEND DON'T BREAK™ technology for impact absorption, an integrated lid locking tab, and patent-pending Vapor Shield Technology to prevent vacuum loss. These improvements are designed to provide better protection for sensitive biological materials during transportation, including cells, tissues, vaccines, and reproductive health materials.
Cryoport (NASDAQ: CYRX) reported Q1 2025 revenue of $41.0 million from continuing operations, up 10% year-over-year. The company's commercial Cell & Gene therapy revenue grew 33%, while Life Sciences Services revenue increased 17%. As of March 31, 2025, Cryoport supported 711 global clinical trials, including 79 in Phase 3. The company announced a strategic partnership with DHL, including the planned divestiture of CRYOPDP expected to close in Q2/Q3 2025.
Financial highlights include a gross margin of 45.4%, operating costs reduction of 13.7%, and a net loss of $12.0 million ($0.28 per share). The company maintains $244.0 million in cash and investments. For fiscal 2025, Cryoport reiterates revenue guidance of $165.0-172.0 million, representing 5-10% growth.